Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
Status:
Completed
Trial end date:
2006-07-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of Icatibant, a bradykinin
antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with
hereditary angioedema (HAE).